Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is temazepam an accumulating hypnotic?

H R Ochs, D J Greenblatt, H Heuer

    Journal of Clinical Pharmacology
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Temazepam, an intermediate half-life benzodiazepine, shows moderate accumulation with repeated dosing. This pharmacokinetic profile is consistent with predictions from single-dose studies, indicating predictable drug behavior.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Response to diazepam in sons of alcoholics.

    Alcoholism, clinical and experimental research·1992
    Same author

    Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone.

    Brain research bulletin·1992
    Same author

    Mental illness, pharmacotherapy, and automobile operation: what is the risk?

    Journal of clinical psychopharmacology·1992
    Same author

    Bioavailability studies of drugs with nonlinear pharmacokinetics: I. Tracer dose AUC varies directly with serum concentration.

    Journal of clinical pharmacology·1992
    Same author

    Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs.

    Journal of veterinary pharmacology and therapeutics·1992
    Same author

    Fluoxetine impairs clearance of alprazolam but not of clonazepam.

    Clinical pharmacology and therapeutics·1992
    Same journal

    FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

    Journal of clinical pharmacology·2026
    Same journal

    Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

    Journal of clinical pharmacology·2026
    Same journal

    New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

    Journal of clinical pharmacology·2026
    Same journal

    Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

    Journal of clinical pharmacology·2026
    Same journal

    The Journal of Clinical Pharmacology: 65 Years of History.

    Journal of clinical pharmacology·2026
    Same journal

    Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

    Journal of clinical pharmacology·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy

    Background:

    • Benzodiazepines are commonly prescribed for anxiety and insomnia.
    • Understanding the pharmacokinetic profile of temazepam is crucial for optimizing therapeutic use and minimizing adverse effects.

    Purpose of the Study:

    • To characterize the pharmacokinetic profile of temazepam after single and multiple oral doses.
    • To evaluate the extent of temazepam accumulation during a seven-day dosing regimen.

    Main Methods:

    • Ten healthy volunteers received a single 20-mg oral dose of temazepam.
    • Serum concentrations were measured using gas chromatography over 48 hours.
    • Subjects then received 20 mg daily for seven days, with pre-dose and post-dose serum levels monitored.

    Main Results:

    Related Experiment Videos

    • Single-dose pharmacokinetics: Vd=1.45 L/kg, t1/2=8.6h, CL=2.33 mL/min/kg.
    • Serum concentrations increased during the first three days of multiple dosing, then plateaued.
    • Mean accumulation ratio was 1.32, significantly greater than unity, with a post-dosage washout half-life of 10.2 hours.

    Conclusions:

    • Temazepam exhibits an intermediate half-life and an intermediate degree of accumulation with multiple dosing.
    • The observed accumulation is consistent with predictions from single-dose pharmacokinetic data.
    • Temazepam's pharmacokinetic profile supports its use as an intermediate-acting benzodiazepine.